$11.90
0.75% yesterday
NYSE, Sep 27, 10:00 pm CET
ISIN
US6031701013
Symbol
MLYS
Sector
Industry

Mineralys Therapeutics Stock price

$11.90
-0.30 2.46% 1M
-0.88 6.89% 6M
+3.30 38.37% YTD
+2.05 20.81% 1Y
-6.54 35.47% 3Y
-6.54 35.47% 5Y
-6.54 35.47% 10Y
NYSE, Closing price Fri, Sep 27 2024
-0.09 0.75%
ISIN
US6031701013
Symbol
MLYS
Sector
Industry

Key metrics

Market capitalization $596.22m
Enterprise Value $285.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.05
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-134.51m
Free Cash Flow (TTM) Free Cash Flow $-97.36m
Cash position $311.12m
EPS (TTM) EPS $-2.69
P/E forward negative
Short interest 4.33%
Show more

Is Mineralys Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Mineralys Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Mineralys Therapeutics forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Mineralys Therapeutics forecast:

Buy
100%

Financial data from Mineralys Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.02 0.02
-
-
-0.02 -0.02
-
-
- Selling and Administrative Expenses 18 18
-
-
- Research and Development Expense 116 116
-
-
-135 -135
-
-
- Depreciation and Amortization 0.02 0.02
-
-
EBIT (Operating Income) EBIT -135 -135
-
-
Net Profit -120 -120
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Mineralys Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mineralys Therapeutics Stock News

Neutral
GlobeNewsWire
3 days ago
– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30 th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension – RADNOR, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medic...
Positive
Seeking Alpha
10 days ago
Mineralys' lorundrostat, a selective aldosterone synthase inhibitor, shows promise in treating resistant hypertension with fewer side effects compared to current MRAs. Upcoming catalysts include pivotal phase 2 and 3 trial results in 2025, with significant potential market impact if successful. Despite a solid cash position, further funding may be needed for regulatory stages, making acquisitio...
Neutral
Seeking Alpha
about 2 months ago
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Richard Law - Goldman Sachs Annabel Samimy - Stifel Mohit Bansal - Wells F...
More Mineralys Therapeutics News

Company Profile

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Head office United States
CEO Jon Congleton
Employees 28
Founded 2019
Website www.mineralystx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today